ACE and Hypertension: The ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension) trial has shown that, in high-risk patients with hypertension, the combination of an ACE inhibitor (benazepril) and a CCB (amlodipine) is superior to that of the ACE inhibitor and HCTZ for the prevention of vascular events [39], while in Japan which FDC regimen is better to attenuate the risks of target organ damage and CV events remains to be established.